A&O Shearman
We are only able to display limited information for this firm. We display more complete information for all of the following firms:
With particular strength in overseeing major healthcare and life sciences transactions, A&O Shearman advises on the acquisitions and disposals of medical and biotech companies, providing comprehensive advice on market regulations, internal restructuring, and post-M&A litigation for clients including private equity investors and healthcare industry leaders alike. The practice group also advises on industry regulations concerning medical devices and drug advertising. Sector lead Alexander Veith is a transactional specialist with experience in corporate law matters at the national and international level as well as in IP disputes, and Eda Zhuleku excels in life sciences regulatory matters such as product reimbursement and clinical trial approvals.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- ‘The healthcare and life sciences team led by Eda Zhuleku is the best team of outside counsels I have ever worked with. Always full of fire for us as a client with pragmatic solutions and helpful guidance. Hands-on support at its best.’
- ‘Eda Zhuleku and Florian Preinfalk are outstanding lawyers. No matter how urgent it is or how tricky the case, I can always rely on the fact that all aspects are taken into account - often even those that you wouldn't have considered yourself - and that a practicable and best possible solution is presented in a concise manner, and in record time.’
Key clients
- Bayer AG
- Kühne Holding AG and E3X Partners GmbH
Work highlights
Coordinated all European patent revocation and infringement proceedings concerning Bayer's patent EP 961, which protects the market for Xarelto following the compound patent expiry in April 2024.